Press Releases.
Month Year
Su | Mo | Tu | We | Th | Fr | Sa |
---|---|---|---|---|---|---|
Month Year
Su | Mo | Tu | We | Th | Fr | Sa |
---|---|---|---|---|---|---|
-
May 04, 2017Company to Restructure Operations Accompanied by a Workforce Reduction
-
April 27, 2017Conference Call and Webcast to Follow
-
March 02, 2017RG-012 development program to include a separate biopsy study, which may provide earlier POC
-
February 23, 2017Conference Call and Webcast to Follow
-
February 16, 2017Published results from preclinical studies show inhibition of miR-17 increased survival and reduced disease burden in mice
-
January 27, 2017FDA requests longer-term follow-up data from ongoing studies
-
November 01, 2016Conference Call Today at 5:00 p.m. ET
-
October 25, 2016Conference Call and Webcast to Follow
-
August 02, 2016Conference Call Today at 5:00 p.m. ET
-
July 27, 2016On Track to Deliver Follow-up Results from On-going RG-101 Studies
-
July 26, 2016Conference Call and Webcast to Follow
-
June 27, 2016Timelines of On-going Studies are not Expected to be Impacted
-
June 07, 2016- Results Demonstrate First Successful Shortened 4-week Treatment Regimen to Date -
-
June 01, 2016- Phase II Study Evaluating the Combination of RG-101 and GSK's Long-Acting Parenteral (LAP) Formulation of GSK2878175 as a potential single-visit cure to begin Q4 2016
-
April 15, 2016- Continued High Virologic Response Rates across All Treatment Arms Out through 24 weeks of Follow Up -
-
March 16, 2016-Oral presentation during general session on interim RG-101 Phase II results & three posters to be presented-
-
February 17, 2016- RG-101 Containing Regimen Has Potential to Reduce Harvoni®, Olysio®, or Daklinza™ Rx to 4 Week Duration -
-
January 21, 2016- Additional studies on track for enrollment in H12016 with multiple data read-outs expected throughout 2016 -
-
December 18, 2015-Regulus Earns $10.0 Million Milestone Payment from AstraZeneca and Achieves Key Goal for 2015-
-
November 05, 2015-Expanded Development of RG-101 through Clinical Trial Collaboration with GSK to Achieve Potential Single Visit HCV Therapy -
-
November 03, 2015- Long-Acting Parenteral Formulation of GSK2878175 Being Developed; Co-Administration with RG-101 May Enable Single Visit Therapy for HCV Patients
-
October 05, 2015RG-012 Shown to Directly Inhibit microRNA-21, Demonstrates Favorable Preclinical Profile Supporting Proof of Mechanism and Clinical Development
-
October 02, 2015-Phase I Clinical Data will be Featured in Viral Hepatitis Plenary Session-